Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  paclitaxel albumin-stabilized nanoparticle formulation
Find trials that include:  Any drugs shown
Results 1-25 of 77 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: ABI-007-NSCL-005, NCI-2014-02488, NCT02151149
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-PANC-003, NCI-2014-00810, 2013-003398-91, NCT01964430
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
Azacitidine and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Advanced or Metastatic Solid Tumors or Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: HCI53993, NCI-2012-01158, 53993, NCT00748553
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Erismodegib before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1130, NCI-2012-00064, CIR00003888, LDE225XUS03T, NA_00047491, NA_00047491 / CIR00004443, NCT01431794
Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 39110-116, NCI-2014-00116, NCT01858883
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13P.387, NCI-2013-01695, 080-38270-J94401, 13C.387, 2013-35, NCT01938833
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
Nab-Paclitaxel, Temozolomide, and Bevacizumab in Treating Patients with Stage III-IV Melanoma with Brain Metastases That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1312169092, NCI-2015-00228, AX-MEL-PI-0019, ML29079, NCI-2015-00145, NCT02065466
Lenalidomide and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S12-02519, NCI-2014-00583, i12-02519, NCT02075021
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NLG2104, NCI-2014-02095, NCT02077881
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
PI3K Inhibitor BYL719 and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER-2 Negative Stage III or IV Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719XUS06T, NCI-2015-00802, STUDY00001632, NCT02379247
Carboplatin and Nab-paclitaxel with Pembrolizumab in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer That is Unable To Be Removed with Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14L01, NCI-2015-00617, HCRN LUN13-175, LUN13-175, NCI-2015-00449, NCT02382406
A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PB1201, NCI-2013-01411, NCT01834235
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 6628, NCI-2010-00041, FHCRC-6628, UWCC-6628, UWHSD# 33866, GENENTECH-FHCRC-6628, NCT00733408
GSK1120212 Rollover Study
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: PGX-ODSH-2011-PC1, NCI-2012-00834, NCT01461915
Start Over